Palifermin is a recombinant human keratinocyte growth factor (KGF) that induces cell growth and exhibits antimucotoxic properties. It can be used to decrease oral mucosal injury induced by cytotoxic research [1] [2] [3].

Palifermin, at concentrations ranging from 0 to 100 ng/mL over a 48-hour incubation period, enhances the proliferation of TE-8 and TE-11 cells, as evidenced by results from the Cell Proliferation Assay [1]. Specifically, while the growth of TE-1 cells remained unaffected, there was a noticeable increase in cell proliferation for TE-8 and TE-11 cell lines under the tested conditions.

Palifermin (10 mg/kg for a single dose or 3 mg/kg administered three times daily over 3 days) reduces diarrhea and increases survival in tumor-bearing DA rats following Irinotecan treatment [2]. Additionally, Palifermin (5 mg/kg; s.c.) is effective against oral mucositis induced by fractionated irradiation in a mouse tongue model [3]. Animal Model (DA rats) [2]: Dosage: 10 mg/kg single dose or 3 mg/kg for 3 times; Administration: Daily for 3 days prior to chemotherapy; Result: Reduced diarrhea and increased survival following Irinotecan treatment. Animal Model (Mouse with 5*3 Gy/week irradiation, tongue model) [3]: Dosage: 5 mg/kg; Administration: S.c., at -3, +4, +11 days, or +4, +11, +18 days, or -3, +4, +11, +18 days; Result: Effective against oral mucositis induced by fractionated irradiation.